Ikonisys S.A.

Equities

ALIKO

FR00140048X2

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 03:00:29 2024-04-25 am EDT			5-day change	1st Jan Change
1.43 ^EUR	0.00%		0.00%	-8.33%

Feb. 19	Ikonisys Says Hospitex Wins Italian Tender for Diagnostic Systems	MT
Jan. 02	Ikonisys: production record for Hospitex	CF

Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2021

April 29, 2022 at 02:23 pm EDT

Ikonisys S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 0.464242 million compared to EUR 0.485167 million a year ago. Net loss was EUR 0.571269 million compared to EUR 1.57 million a year ago.

Latest news about Ikonisys S.A.

Ikonisys Says Hospitex Wins Italian Tender for Diagnostic Systems	Feb. 19	MT
Ikonisys: production record for Hospitex	Jan. 02	CF
Ikonisys: private placement for one million euros	Dec. 29	CF
Diagnostics Group Ikonisys Raises EUR1 Million Via Share Issue	Dec. 29	MT
Ikonisys S.A. Announces the Completion of ?1 Million Private Placement to Speed Up Growth Following Recent Pivotal Deals	Dec. 28	CI
Ikonisys S.A. announced that it expects to receive ?1.000001 million in funding	Dec. 26	CI
Hospitex International, Pathologists Beyond Borders Association Team Up to Develop Early Cancer Diagnosis Systems	Dec. 15	MT
Ikonisys Strikes EUR5 Million Deal to Buy Italian Peer Hospitex International	Nov. 30	MT
Ikonisys S.A. entered into an agreement to acquire Hospitex International S.R.L. for ?3.5 million.	Nov. 29	CI
Ikonisys SA and Biocare Medical Forge Alliance	23-10-31	CI
Ikonisys S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-30	CI
Ikonisys US Subsidiary Completes ISO Recertification	23-10-17	MT
Ikonisys Completes Study for Immuno-Oncology Platform to Detect Extremely Rare Cells	23-10-10	MT
Ikonisys Raises New Financing Via Columbia Threadneedle	23-08-04	MT
Ikonisys SA Announces Completion of New Financing via the Issuance of a EUR 0.5 Million Private Note	23-08-03	CI
Ikonisys S.A. announced that it has received ?0.5 million in funding	23-08-02	CI
Ikonisys Signs Distribution Deal With Integrated Gulf Biosystems Group	23-07-31	MT
Ikonisys Secures Sale, Installation of Ikoniscope20max in US	23-07-28	MT
Ikonisys Announces the Successful Deployment of the Commercial Strategy With the Second Sale of the Ikoniscope20max Solution	23-07-28	CI
Ikonisys SA Announces the First Sale of the Ikoniscope20max Solution	23-06-21	CI
Ikonisys Completes Private Placement of Shares with Investors	23-06-15	MT
Ikonisys S.A. announced that it has received €0.5 million in funding from Cambria Equity Partners, L.P.	23-06-13	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	23-05-02
Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-29	CI
Ikonisys S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-29	CI

Chart Ikonisys S.A.

Duration

Period

More charts

Company Profile

Ikonisys S.A. is specialized in the design, manufacture and marketing of medical diagnostic equipment. The company offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. Net sales break down by source of revenue as follows: - sales of products (65.3%): sales of Ikoniscope instruments and the related software application; - sales of maintenance services (34.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-28 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ikonisys S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.43 EUR

Average target price

6.3 EUR

Spread / Average Target

+340.56%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
IKONISYS S.A.	-8.33%	15.97M
BIOMÉRIEUX	-0.50%	12.72B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-11.57%	7.5B
DIASORIN S.P.A.	+1.65%	5.48B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.98%	4.61B
LANTHEUS HOLDINGS, INC.	+5.18%	4.47B
10X GENOMICS, INC.	-50.82%	3.28B
ANDON HEALTH CO., LTD.	+11.23%	2.71B
VITROLIFE AB	-15.41%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-10.84%	1.74B

Diagnostic & Testing Substances